Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
over 02 on good volume maybe a surprise is coming
Seems like some deep pockets are running this one . Impressive uptrend atm
Totally agree with you x-ray-eyes
Some serious whale action here atm I got a few 100k to start
It was inevitable, all we need is a handful of deep pocket Biotech peeps, imo
It's great to see everything finally coming to fruition JMC$ buddy. Patients are a must for all Biotech's stocks
TSOI back in the .02 saddle again ready to ride north subs
GM JMC$ we got big boys backing us!
TSOI lets churn slowly until .025, then we breakout, $$$, imo
MM's may defer from swapping and dropping with $$$ Bids, imo
subs, good morning TSOI green over 12% up so far this morning
5mm wanted at .019, Love it! Huge bid keeps moving up!
Trading strong see a big bid and acsm top of bid
TSOI here we go, lets get that Whale bid up, $$$$
TSOI slow and steady, Volume should pick up after .018, imo
Sweet...I'll take a climb anytime...just hope it remains a new and growing base.
Stock is up 40% last few days and this place is a morgue ……where’s all the debate the conjecture the banter the discussion on 10m share bids ??? It can lose 5% for 2 days in a row and there’s panic in the streets and scores of messages ….today for being up 30% ….crickets ….
Hi subs, TSOI up 30% GREEN today, nice
Yup JMC$ sure looks good.
Whale Bid moving up, maybe a QuadraMune Squeeze coming
Thoughts on the huge bids coming in a few times a week, is this the funding buying on the open market? If so, I think this strategy is marvelous...The funding is slowly driving the share price up, killing any type of shorts that "might" exist, giving the funder value for their purchase. Its a long term investment in a company with soo much potential....Love it...Here's to the Investors!
TSOI SEC filings
https://www.sec.gov/edgar/browse/?CIK=1419051&owner=exclude
Well we traded under 2mm shares and it closed green...so there's that!
Always remember folks, look up history. I sheds a lot of light.
TSOI: So, how is the (disruptive) "THERAPEUTIC DILUTIONS" Company doing today?? Yet more Patents Pending??? Or perhaps, yet another "NAIVE Mice" study??? (Myself, I like sophisticated, WORLDLY Mice!!!)
Don't ya just LOVE TSOI's 'Prime Directive'?? To wit, that they can CURE complex Psychiatric disorders with simple pills and/or injections!!!
Heck, that ain't nothin'!!! Conversely, MY company can CURE Cancer, Heart Disease, Stroke, Diabetes, the Covids, Monkey Pox, & the Human Aging Process itself, inter alia, with simple Psychological COUNSELING!!!!
same to you Yoop !
Trying out their products is part of the DD. If someone is into thousands of dollars of investment money, it's an indicator .
and product reviews are another area of DD also .
pretty much the basis of what you and I know already Re: the trying out of their nutras.
their stem cells are for those into a longer vibe . 18 months thru the patent process is a clue in .
there are many I know of that are waiting here for this one to see an explosion .
Risk and reward for those in tune with that vibe.
-imho
-Cents
thanks Subs,
It takes me some time to digest the PRs as they can get pretty technical .
I asked Tim on the forum and this was his reply :
Post by TimGDixon » Tue Oct 04, 2022 3:35 am
Yes you are on the right track, however what is novel about our discovery is that we were able to do this beginning with a JadiCell.
On October 03, 2022, the Company filed a patent application titled “Stimulation of Pulmonary Regenerative Exosomes by Mesenchymal Stem Cells and Derivatives Thereof” which discloses therapeutic means for pulmonary degenerative conditions through the administration of mesenchymal stem cells in order to induce regenerative exosomes from dendritic cells expressing CD103. In one embodiment cultures of mesenchymal stem cells with dendritic cell progenitors are disclosed wherein said mesenchymal stem cells induce a modulation of STAT3 signaling in said dendritic cell endowing a regenerative property to said dendritic cells and exosomes derived from said cells.
Thank you cents. Always a great readout from you!
In a series of experiments, it was found that protection against both Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS) could be transferred to naïve mice by dendritic cells expressing the molecule CD103.
Agreed.
Fortune favors the bold.
TSOI
Thanks subs, TSOI getting closer every day
“While the field of exosome therapeutics is growing exponentially, the use of dendritic cell exosomes for respiratory conditions is completely unheard of.”
TSOI: WRONG! Pure BULLSHIT "news", again!! NEVER heard such nonsense verbiage from so-called "Scientists" in my life!!! Absolutely LAUGHABLE!!
https://www.businesswire.com/news/home/20221003005541/en/
Nice news TSOI news https://www.businesswire.com/news/home/20221003005541/en/
NEWS
Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection
Clinical Stage Stem Cell Company Leverages Knowledge Gained from Cancer Dendritic Cell Therapy StemVacs to Open New Door for COPD and ARDS Research
ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today new data suggesting that therapeutic effects of its universal donor stem cell product are mediated in part through CD103 expressing dendritic cells.
In a series of experiments, it was found that protection against both Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS) could be transferred to naïve mice by dendritic cells expressing the molecule CD103. Furthermore, exosomes, which are nanoparticles produced by cells, were capable of transferring protection to naïve mice.
“I am pleased to have worked with a team of opinion leaders that are at the cutting edge to have discovered this quite unexpected finding,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “While the field of exosome therapeutics is growing exponentially, the use of dendritic cell exosomes for respiratory conditions is completely unheard of.”
Therapeutic Solutions International is currently running a Phase III clinical trial using JadiCells in the treatment of COVID-19 associated ARDS. Additionally, the Company has an Investigational New Drug Application IND# 28508 for treatment of COPD, for which the Company is still in discussions with the FDA.
“Dr. Veltmeyer has performed unparalleled work in advancing both clinical translation of the JadiCell, as well as leveraging scientific lessons learned from our cancer program to identify a new mechanism by which our cells exert this previously unknown therapeutic efficacy,” said Timothy Dixon, President, and CEO of the Company. “Having filed our patent today on this new finding, we anticipate potential development of adjuvant products around dendritic cell generated exosomes.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
https://cts.businesswire.com/ct/CT?id=bwnews&sty=20221003005541r1&sid=acqr8&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005541/en/
I hate to ask this but we all down here are in an argument of whether phase 3 and enrollment has started. Does anyone have a link saying it has or hasn’t from someone other than management. Three or four of us have got a great chance of picking up some a great chunk of change on the links.
We all agree this is going to be one fantastic stock someday if it’s ran right. We all agree it could be an Amazon in the bio field at some point in time.
Bavituximab is embodied in TSOI patent #9,682,047
https://patents.justia.com/patent/9682047
Said cancer drugs may also include one or more of the following monoclonal antibodies used for treating various types of cancer: 3F8, 8H9, Abagovomab, Abituzumab, Adecatumumab, Afutuzumab, Amatuximab, Anatumomab mafenatox, Anetumab ravtansine, Apolizumab, Arcitumomab, Ascrinvacumab, Atezolizumab, Bavituximab, Bevacizumab, Bivatuzumab mertansine, Blinatumomab, Brentuximab vedotin, Brolucizumab, Brontictuzumab, Cantuzumab mertansine, Cantuzumab ravtansine, Catumaxomab, Cetuximab, Cixutumumab, Zatuximab, Votumumab, Vorsetuzumab mafodotin, Volociximab, Vanucizumab, Vantictumab, Vandortuzumab vedotin, Urelumab, Ulocuplumab, Ublituximab, Tucotuzumab celmoleukin, Tremelimumab, TRBS07, Trastuzumab, Tigatuzumab, Ticilimumab, Tenatumomab, Tarextumab, Taplitumomab paptox, Tacatuzumab tetraxetan, Sofituzumab vedotin, Siltuximab, SGN-CD33A, SGN-CD19A, Sibrotuzumab, Robatumumab, Rituximab, Rilotumumab, Ramucirumab, Radretumab, Pritumumab, Pidilizumab, Pertuzumab Omnitarg, Lumretuzumab, Isatuximab, Ipilimumab, Enavatuzumab, Edrecolomab, Duligotumab, and Clivatuzumab.
Dr. Phil Thorpe developed bavituximab many years ago for cellular targeting of cancer. He’s since died but bavituximab still being tested.
Dilution with a bow on it without any filings to prove it? Hmmmm!!!
It’s just. Dilution with a pretty bow
as per GHS Purchase Agreement "Freely" NO Use of Rule 144
GHS Purchased Shares Freely Tradable w/o restrictions on resale
b) Settlement for Purchase Shares
All Purchase Shares issued hereunder will be DWAC Shares.
DWAC Shares means shares of Common Stock that are (i) issued in electronic form. (ii)freely tradable and without restriction on resale and (iii) timely credited by the company to the Investor's or it's designee's specific Deposit Withdrawal at Custodian (DWAC) account with DTC under it's Fast Automated Securities Transfer (FAST) Program, or any similar program hereafter adopted by DTC performing substantially the same function.
(e) Commitment Shares means five million (5,000,000) common stock issued upon the initial closing as an equity incentive
(t)Purchase Price means with respect to a Purchase made pursuant to Section 2(a) hereof 80% of the lowest traded price of Common Stock during the Valuation Period.
(bb) Valuation Period means the ten (10)consecutive Business Days immediately preceding, but not including the Settlement date. [/color]
that doesn't really matter squat.
why would
dixon change ? Cmon , really ?
why wouldn't the data from Phase 3 change it ? :)
great stuff Curncman
GHS Inc would not be able to buy 10 million worth of shares in the open market without PPS shooting up to 15 cents instead they would be happy to get them at PPS between 5 to 10 cents with direct allotment from the company.
a real discussion of this stock :)
and tim's reply was:
EXHIBIT A
FORM OF PURCHASE NOTICE
________, 202__
To: GHS Investments, LLC
In accordance with Section 2 of the purchase agreement, dated September [ ], 2022 (the “Purchase Agreement”),
between Therapeutic Solutions International, Inc. (the “Company”) and GHS Investments, LLC (the “Investor”), the
Company hereby provides notice to the Investor of a sale by the Company to the Investor of Purchase Shares in the
amount set forth in this Purchase Notice. Capitalized terms used herein have the meanings set forth in the Purchase
Agreement.
Purchase Amount: $___________
Purchase Price per share: $____________
Number of Purchase Shares: __________
Very truly yours,
Therapeutic Solutions International, Inc.
By:_________________________
Name:
Title:
Followers
|
528
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
64728
|
Created
|
10/04/08
|
Type
|
Free
|
Moderators BigBadWolf johnnytrader33 JMC$ Yooperman Hogwarts |
Preclinical Data Suggests QuadraMune™ Prevents Stress-Induced Suppression of Neurogenesis More Effectively than Prozac
OCEANSIDE, Calif., Dec. 9, 2020 /PRNewswire/ -- Therapeutics Solution International, Inc., (OTC Markets: TSOI), announced today new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
The experiments, which involved exposing mice to established stressors, demonstrated that specific areas of the brain associated with production of new brain cells are damaged by stress. In agreement with previously published research, administration of fluoxetine (Prozac™) protected the brain from stress-induced damage. Surprisingly, QuadraMune™ administration appeared superior to Prozac™ at stimulating proliferation of new brain cells.
"QuadraMune™ which is currently in a clinical trial for prevention of COVD-191, has also been demonstrated to possess anti-inflammatory activity in other clinical trials, suppressing cytokines such as IL-62, which are known to be involved in depression3 and suicide4" said Kalina O'Connor, Director of Campbell Neurosciences and co-inventor on the patent. "Given major depressive disorder causes a significant risk for suicide, we are highly interested in exploring the use of QuadraMune™ for preventing suicide."
"Although much enthusiasm has been generated over the planned distribution of the COVID vaccine, at present little is being done to address mental health issues that are being exacerbated by the current pandemic" said Dr. James Veltmeyer, co-inventor of the patent, and Chief Medical Officer of the Company. "If current results are reproducible, the possibility that a nutraceutical would concurrently boost immunity while preserving mental health is highly enticing."
"It has not escaped us that COVID-19 is associated with increased inflammatory cytokines in the blood of patients, cytokines that also predispose to depression" said Famela Ramos, Vice President of Business Development for the Company. "It may be that the recent increase in suicides and suicide attempts is related biologically to activities of the coronavirus. It will be interesting to examine whether QuadraMune™ may modify putative negative mental effects of the virus."
"An estimated 17.3 million adults in the United States had at least one major depressive episode. This number represented 7.1% of all U.S. adults" stated Timothy Dixon, President and CEO of the Company. "We believe the Mission of our Company is not just providing a return on investment to our shareholders, but also increasing the quality of life for Americans. We are extremely pleased to report this unexpected finding with significant potential implications to advancing non-toxic means of helping patients with this terrible condition."
1 QuadraMune(TM) for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov
2 Therapeutic Solutions International Announces Positive Preclinical and Clinical Evaluation of Nutritional Supplement QuadraMune™, Designed to Protect Against COVID-19 | BioSpace
3 Ting et al. Role of Interleukin-6 in Depressive Disorder. Int J Mol Sci. 2020 Mar 22;21(6):2194.
4 O'Donovan et al. Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 2013 Apr;30(4):307-14.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |